

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human MCM7 in direct ELISAs and Western blots.
Source	Monoclonal Rabbit IgG Clone # 2068B
Purification	Protein A or G purified from cell culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human MCM7 Gly188-Ala328 Accession # P33993
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Intracellular Staining by Flow Cytometry	0.25-1 µg/10 ⁶ cells	HeLa human cervical epithelial carcinoma cell line fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012)

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

MCM7/minichromosome maintenance complex component 7, is a highly conserved mini-chromosome maintenance protein, with ATP binding, DNA helicase activity and single-stranded DNA binding. MCM7 forms a hexameric protein complex with MCM2, 4 and 6 proteins that has DNA helicase activity essential for the initiation of gene replication. MCM7 also binds to RAD17 to mediate ATR recruitment to damaged DNA. MCM7 expression is repressed in quiescent cells but induced in late G1 to S phase by growth factor stimulation. It is up-regulated in many cancers including colorectal, T cell lymphomas, glioblastoma, and has prognostic value for hepatocellular carcinoma and gastric adenocarcinoma.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.